” The results suggest that low dosing of benzbromarone might require stronger factor to consider as a efficient and safe therapy to achieve serum urate target in gout,” the authors wrote.
Referral: “Superiority of low-dose benzbromarone to low-dose febuxostat in a potential, randomized relative effectiveness trial in gout clients with renal uric acid underexcretion” by Fei Yan MD, Xiaomei Xue MD, Jie Lu MD, Nicola Dalbeth MD, Han Qi MS, Qing Yu MS, Can Wang MD, Mingshu Sun MD, Lingling Cui Ph.D., Zhen Liu Ph.D., Yuwei He Ph.D., Xuan Yuan MD, Ying Chen MD, Xiaoyu Cheng MD, Lidan Ma MD, Hailong Li Ph.D., Aichang Ji Ph.D., Shuhui Hu MS, Zijing Ran MS, Robert Terkeltaub Ph.D. and Changgui Li MD, 7 July 2022, Arthritis & & Rheumatology.DOI: 10.1002/ art. 42266.
The authors of the study believe that a drug called benzbromarone might be an improved way to deal with gout.
Should doctors reconsider the standard gout treatment?
Gout is triggered by the build-up of urate crystals in the joints, and xanthine oxidase inhibitors such as febuxostat are a staple treatment to help lower blood urate levels in affected people. Nevertheless, a brand-new medical trial reported in Arthritis & & Rheumatology suggests that benzbromarone, a less popular medication, may be better in low does.
In the prospective single-center, open-labeled trial, 196 guys with gout and bad uric acid excretion were randomized to receive either low-dose benzbromarone (LDBen) or low-dose febuxostat (LDFeb) for 12 weeks.
Compared to the LDFeb group, more people in the LDBen group satisfied the blood urate objective of 6 mg/dL (32% vs 61%). There was no significant difference in adverse effects across the groups.
